CA3066279A1 - Nucleic acids and corresponding proteins entitled 191p4d12(b) useful in treatment and detection of cancer - Google Patents

Nucleic acids and corresponding proteins entitled 191p4d12(b) useful in treatment and detection of cancer Download PDF

Info

Publication number
CA3066279A1
CA3066279A1 CA3066279A CA3066279A CA3066279A1 CA 3066279 A1 CA3066279 A1 CA 3066279A1 CA 3066279 A CA3066279 A CA 3066279A CA 3066279 A CA3066279 A CA 3066279A CA 3066279 A1 CA3066279 A1 CA 3066279A1
Authority
CA
Canada
Prior art keywords
seq
protein
antibody
peptide
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA3066279A
Other languages
English (en)
French (fr)
Inventor
Arthur B. Raitano
Pia Challita-Eid
Aya Jakobovits
Mary Faris
Wangmao Ge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Publication of CA3066279A1 publication Critical patent/CA3066279A1/en
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
CA3066279A 2002-08-16 2003-04-23 Nucleic acids and corresponding proteins entitled 191p4d12(b) useful in treatment and detection of cancer Expired - Lifetime CA3066279A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40430602P 2002-08-16 2002-08-16
US60/404,306 2002-08-16
US42329002P 2002-11-01 2002-11-01
US60/423,290 2002-11-01
CA2493923A CA2493923C (en) 2002-08-16 2003-04-23 Nucleic acids and corresponding proteins entitled 191p4d12(b) useful in treatment and detection of cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2493923A Division CA2493923C (en) 2002-08-16 2003-04-23 Nucleic acids and corresponding proteins entitled 191p4d12(b) useful in treatment and detection of cancer

Publications (1)

Publication Number Publication Date
CA3066279A1 true CA3066279A1 (en) 2004-02-26

Family

ID=31891426

Family Applications (5)

Application Number Title Priority Date Filing Date
CA3066279A Expired - Lifetime CA3066279A1 (en) 2002-08-16 2003-04-23 Nucleic acids and corresponding proteins entitled 191p4d12(b) useful in treatment and detection of cancer
CA2493923A Expired - Lifetime CA2493923C (en) 2002-08-16 2003-04-23 Nucleic acids and corresponding proteins entitled 191p4d12(b) useful in treatment and detection of cancer
CA2493921A Expired - Lifetime CA2493921C (en) 2002-08-16 2003-05-09 Nucleic acids and corresponding proteins entitled 282p1g3 useful in treatment and detection of cancer
CA002493925A Abandoned CA2493925A1 (en) 2002-08-16 2003-06-16 Nucleic acids and corresponding proteins entitled 202p5a5 useful in treatment and detection of cancer
CA2493928A Expired - Fee Related CA2493928C (en) 2002-08-16 2003-08-15 Nucleic acids and corresponding proteins entitled 273p4b7 useful in treatment and detection of cancer

Family Applications After (4)

Application Number Title Priority Date Filing Date
CA2493923A Expired - Lifetime CA2493923C (en) 2002-08-16 2003-04-23 Nucleic acids and corresponding proteins entitled 191p4d12(b) useful in treatment and detection of cancer
CA2493921A Expired - Lifetime CA2493921C (en) 2002-08-16 2003-05-09 Nucleic acids and corresponding proteins entitled 282p1g3 useful in treatment and detection of cancer
CA002493925A Abandoned CA2493925A1 (en) 2002-08-16 2003-06-16 Nucleic acids and corresponding proteins entitled 202p5a5 useful in treatment and detection of cancer
CA2493928A Expired - Fee Related CA2493928C (en) 2002-08-16 2003-08-15 Nucleic acids and corresponding proteins entitled 273p4b7 useful in treatment and detection of cancer

Country Status (12)

Country Link
US (16) US20040081653A1 (enExample)
EP (6) EP2332966A1 (enExample)
JP (6) JP2006513724A (enExample)
AU (6) AU2003243151A1 (enExample)
CA (5) CA3066279A1 (enExample)
CY (1) CY1113247T1 (enExample)
DK (2) DK1576170T3 (enExample)
ES (2) ES2392341T3 (enExample)
IL (6) IL166531A (enExample)
PT (2) PT1576170E (enExample)
SI (2) SI1576170T1 (enExample)
WO (5) WO2004016733A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US7678889B2 (en) * 2002-08-06 2010-03-16 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
WO2005054860A1 (en) * 2003-12-01 2005-06-16 Dako Denmark A/S Methods and compositions for immuno-histochemical detection
US20060019396A1 (en) * 2004-06-07 2006-01-26 Tissuegene, Inc. Retroviral vectors with enhanced efficiency of transgene expression and safety
NZ566395A (en) * 2005-09-26 2012-03-30 Medarex Inc Human monoclonal antibodies to CD70
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
WO2008074004A2 (en) * 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
JP2010519256A (ja) * 2007-02-23 2010-06-03 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 免疫疾患を治療するために、ＨＬＡ−Ｅ／Ｑａ−１拘束性ＣＤ８＋Ｔ細胞制御性経路を活性化または遮断する方法
EA201070231A1 (ru) 2007-08-09 2010-10-29 Синтоникс Фармасьютикалз, Инк. Иммуномодулирующие пептиды
CA2758964A1 (en) * 2009-04-16 2010-10-21 Abbott Biotherapeutics Corp. Anti-tnf-.alpha. antibodies and their uses
WO2011028257A1 (en) * 2009-08-24 2011-03-10 The Trustees Of Columbia University In The City Of New York Assay for determining health of cd8+ t cells
WO2011112599A2 (en) 2010-03-12 2011-09-15 The United States Of America, As Represented By The Secretary. Department Of Health & Human Services Immunogenic pote peptides and methods of use
US8449512B2 (en) 2010-04-09 2013-05-28 Davinci Biomedical Research Products Inc. Stoma stabilitating device and method
KR20250058780A (ko) * 2010-09-29 2025-04-30 어젠시스 인코포레이티드 191p4d12 단백질에 결합하는 항체 약물 컨쥬게이트(ａｄｃ)
EP2712423A4 (en) * 2011-02-25 2015-06-10 Wellstat Diagnostics Llc Assays for detecting enzymatic activity
WO2012164004A1 (en) 2011-06-01 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel antigen peptide and uses thereof
US9314500B2 (en) 2011-10-12 2016-04-19 The General Hospital Corporation Non-N-glycosylated recombinant human annexin A2
CA2893977C (en) 2012-12-21 2024-02-13 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
US9944689B2 (en) 2013-03-07 2018-04-17 The General Hospital Corporation Human CTLA4 mutants and use thereof
WO2015114633A1 (en) * 2014-01-30 2015-08-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
IL297418B2 (en) 2015-02-18 2023-11-01 Enlivex Therapeutics Rdo Ltd Combined immunotherapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
AU2016250570B2 (en) 2015-04-21 2021-07-01 Enlivex Therapeutics Rdo Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP6884155B2 (ja) 2016-02-18 2021-06-09 エンリヴェックス セラピューティクス リミテッド 癌治療のための併用免疫療法及びサイトカイン制御療法
WO2018035046A1 (en) 2016-08-15 2018-02-22 President And Fellows Of Harvard College Treating infections using idsd from proteus mirabilis
US10350280B2 (en) * 2016-08-31 2019-07-16 Medgenome Inc. Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
KR102089072B1 (ko) 2017-01-06 2020-03-17 주식회사 유틸렉스 항-인간 4-1bb 항체 및 그의 용도
JP7106810B2 (ja) * 2018-04-19 2022-07-27 学校法人 埼玉医科大学 新規肺がんマーカー
CA3100946A1 (en) 2018-05-22 2019-11-28 The Brigham And Women's Hospital, Inc. Gene therapy for alzheimer's disease
CN108875628A (zh) * 2018-06-14 2018-11-23 攀枝花学院 行人检测方法
TWI894130B (zh) 2018-12-03 2025-08-21 美商艾澤西公司 包含抗191p4d12抗體藥物結合物之醫藥組合物及其使用方法
WO2020174368A1 (en) 2019-02-25 2020-09-03 Novartis Ag Compositions and methods to treat bietti crystalline dystrophy
EP3931335A2 (en) 2019-02-25 2022-01-05 Novartis AG Compositions and methods to treat bietti crystalline dystrophy
CN110147939B (zh) * 2019-04-24 2022-04-08 中国食品药品检定研究院 一种仿制药品的工艺评价方法和系统
US12491267B2 (en) 2019-11-29 2025-12-09 The Brigham And Women's Hospital, Inc. Gene therapy for neurodegenerative disorders
CA3193584A1 (en) 2020-09-04 2022-03-10 Novarock Biotherapeutics, Ltd. Nectin-4 antibodies and uses thereof
EP4384279A1 (en) * 2021-08-13 2024-06-19 Agensys, Inc. Methods for treating non-muscle invasive bladder cancer (nmibc) with antibody drug conjugates (adc) that bind to 191p4d12 proteins

Family Cites Families (252)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6903384A (enExample) 1969-03-05 1970-09-08
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5359100A (en) 1987-10-15 1994-10-25 Chiron Corporation Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US5254678A (en) 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
ATE123780T1 (de) * 1989-02-17 1995-06-15 Chiron Mimotopes Pty Ltd Verfahren zur verwendung und herstellung von peptiden.
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
JPH04503957A (ja) 1989-03-07 1992-07-16 ジェネンテク，インコーポレイテッド 脂質とオリゴヌクレオチドの共有結合コンジュゲート
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0800830A3 (en) 1989-11-03 1999-03-17 Vanderbilt University Method of in vivo delivery of functioning foreign genes
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
ES2164045T3 (es) 1990-06-27 2002-02-16 Univ Princeton Sondas para la deteccion de p53 mutante.
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
SE9002480D0 (sv) 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
WO1993016178A2 (en) 1992-02-12 1993-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sequences characteristic of human gene transcription product
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
AU4528493A (en) 1992-06-04 1994-01-04 Regents Of The University Of California, The In vivo gene therapy with intron-free sequence of interest
EP0656788B1 (en) 1992-08-07 2006-10-18 Pharmexa Inc. Hla binding peptides and their uses
JP3472587B2 (ja) * 1992-08-28 2003-12-02 アベンティス ファーマ株式会社 骨関連カルボキシペプチダーゼ様タンパク質およびその製造法
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5652138A (en) * 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
DE69314148T2 (de) 1992-12-17 1998-01-15 Valeo Systemes Essuyage Stromversorgungsverfahren und -vorrichtung für einen elektrischen Motor zum Antrieb eines Scheibenwischers eines Kraftfahrzeugs
US5576220A (en) 1993-02-19 1996-11-19 Arris Pharmaceutical Corporation Thin film HPMP matrix systems and methods for constructing and displaying ligands
DE69435292D1 (de) 1993-03-05 2010-06-17 Epimmune Inc Verfahren zur herstellung von immunogenen hla-a2.1-bindenden peptiden
CN1127527A (zh) 1993-05-17 1996-07-24 加利福尼亚大学董事会 人免疫缺陷型病毒感染和艾滋病的核酶基因治疗方法
US5837501A (en) 1993-07-09 1998-11-17 Akzo Nobel N.V. Nucleic acid quantitation by co-amplification of target with multiple internal controls
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
WO1995007707A1 (en) 1993-09-14 1995-03-23 Cytel Corporation Alteration of immune response using pan dr-binding peptides
US5681697A (en) 1993-12-08 1997-10-28 Chiron Corporation Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor
CH686982A5 (fr) 1993-12-16 1996-08-15 Maurice Stroun Méthode pour le diagnostic de cancers.
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US6004746A (en) 1994-07-20 1999-12-21 The General Hospital Corporation Interaction trap systems for detecting protein interactions
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5681702A (en) 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5614372A (en) * 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
DE69636866D1 (en) 1995-04-11 2007-03-15 Gen Hospital Corp Reverse "two-hybrid"-systeme
DE69637677D1 (de) 1995-04-14 2008-10-23 Univ Alabama Res Found Transfer system basierend auf einem fusionsprotein und seine anwendungen.
PL322947A1 (en) 1995-04-19 1998-03-02 Acorda Therapeutics Growth modulators capable to modulate growth of central nervous system axones as well as compositiona and cells for and method of obtaining und using them
US6576607B1 (en) * 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US5759776A (en) * 1995-06-05 1998-06-02 California Pacific Medical Center Targets for breast cancer diagnosis and treatment
US5861160A (en) * 1995-06-07 1999-01-19 Ambico, Inc. Isospora suis sporozoite antigen
US5585639A (en) 1995-07-27 1996-12-17 Hewlett-Packard Company Optical scanning apparatus
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6248555B1 (en) * 1995-08-31 2001-06-19 The General Hospital Corporation Genetic alterations related to familial alzheimer's disease
NZ330887A (en) 1996-01-11 2001-01-26 Corixa Corp Monoclonals and polyclonals antibodies for the diagnosis of breast cancer
US6344550B1 (en) * 1996-01-11 2002-02-05 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US7241876B2 (en) * 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US20030125536A1 (en) 1996-01-11 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US20020068285A1 (en) 1996-01-11 2002-06-06 Frudakis Tony N. Compositions and methods for the therapy and diagnosis of breast cancer
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
ATE511849T1 (de) 1996-03-11 2011-06-15 Epimmune Inc Peptide mit erhöhter bindungsaffinität für mindestens drei hla-a3-ähnliche moleküle
WO1997041255A1 (en) 1996-04-26 1997-11-06 Massachusetts Institute Of Technology Three-hybrid screening assay
CA2262006A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
WO1998014569A1 (en) * 1996-10-02 1998-04-09 Bloch Donald B Leukocyte-specific protein and gene, and methods of use thereof
US6365797B1 (en) 1997-10-15 2002-04-02 The Regents Of The University Of California Mice models of human prostate cancer progression
ES2290964T3 (es) 1996-10-15 2008-02-16 The Regents Of The University Of California Modelos animales de la evolucion del cancer de prostata humano.
US5846722A (en) 1996-10-16 1998-12-08 Terrapin Technologies, Inc. System to detect small molecule/peptide interaction
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US7033827B2 (en) * 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6800746B2 (en) * 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7026447B2 (en) * 1997-10-09 2006-04-11 Human Genome Sciences, Inc. 53 human secreted proteins
ZA982968B (en) 1997-04-09 1998-10-27 Corixa Corp Compositions and methods for the treatment and diagnosis of breast cancer
JP2001519666A (ja) 1997-04-10 2001-10-23 ジェネティックス・インスチチュート・インコーポレーテッド 分泌発現配列タグ（ｓＥＳＴｓ）
JP2001519667A (ja) 1997-04-10 2001-10-23 ジェネティックス・インスチチュート・インコーポレーテッド 分泌発現配列タグ（ｓＥＳＴｓ）
PT973550E (pt) * 1997-04-11 2003-01-31 Searle & Co Anticorpos antagonistas anti-integrina avb3
AU8555198A (en) 1997-08-01 1999-02-22 Genset 5' ests for secreted proteins expressed in prostate
EP1042342A4 (en) 1997-10-09 2003-04-09 Human Genome Sciences Inc 53 PROTEINS OF HUMAN ORIGIN
ATE440951T1 (de) 1997-12-17 2009-09-15 Serono Genetics Inst Sa Verlängerte cdns, die für sekretierte proteine kodieren
US20030215803A1 (en) 2000-12-07 2003-11-20 Garcia Pablo Dominguez Human genes and gene expression products isolated from human prostate
ID27813A (id) * 1998-01-28 2001-04-26 Corixa Corp Senyawa-senyawa untuk terapi dan diagnosa kanker paru-paru dan metoda untuk penggunaannya
JP2002519000A (ja) 1998-01-28 2002-07-02 カイロン コーポレイション ヒト遺伝子および遺伝子発現産物ｉｉ
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression
US6531279B1 (en) * 1998-04-15 2003-03-11 Genset S.A. Genomic sequence of the 5-lipoxygenase-activating protein (FLAP), polymorphic markers thereof and methods for detection of asthma
US6476212B1 (en) * 1998-05-26 2002-11-05 Incyte Genomics, Inc. Polynucleotides and polypeptides derived from corn ear
US20030118599A1 (en) * 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
KR20010083111A (ko) 1998-07-14 2001-08-31 길리스 스티브 전립선암의 치료 및 진단을 위한 조성물 및 방법
AU6263999A (en) 1998-09-28 2000-04-17 Chiron Corporation Human genes and gene expression products
US6264949B1 (en) * 1998-09-29 2001-07-24 Mount Sinai School Of Medicine Of New York University Noninvasive agents for diagnosis and prognosis of the progression of fibrosis
AU1208200A (en) 1998-10-15 2000-05-01 Genetics Institute Inc. Secreted expressed sequence tags (sests)
WO2001088088A2 (en) * 2000-05-18 2001-11-22 Hyseq, Inc. Novel nucleic acids and polypeptides
US20020137160A1 (en) * 1998-12-17 2002-09-26 Byatt John C Nucleic acid and other molecules associated with lactation and muscle and fat deposition
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
CA2368482A1 (en) 1999-03-26 2000-10-05 Craig A. Rosen 50 human secreted proteins
CA2383592A1 (en) 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
JP2002540790A (ja) 1999-04-02 2002-12-03 コリクサ コーポレイション 肺癌の治療および診断のための化合物ならびにその使用のための方法
WO2000061753A2 (en) 1999-04-09 2000-10-19 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
EP1268758A2 (en) 1999-06-01 2003-01-02 Incyte Genomics, Inc. Molecules for diagnostics and therapeutics
US7160694B2 (en) * 1999-06-14 2007-01-09 Millennium Pharmaceuticals, Inc. Nucleic acids encoding TANGO405 and functional fragments and uses thereof
US6114123A (en) * 1999-06-14 2000-09-05 Incyte Pharmaceuticals, Inc. Lipocalin family protein
EP1130094A3 (en) 1999-07-08 2001-11-21 Helix Research Institute Primers for synthesizing full length cDNA clones and their use
JP2002191363A (ja) * 1999-07-29 2002-07-09 Herikkusu Kenkyusho:Kk 全長ｃＤＮＡ合成用プライマー、およびその用途
EP1074617A3 (en) * 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
WO2001018176A1 (en) * 1999-09-03 2001-03-15 Human Genome Sciences, Inc. Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies
EP1218392A4 (en) * 1999-09-10 2003-04-09 Millennium Pharm Inc GENE THE PROTEINS ENCODE WHICH PROGNOSTIC, DIAGNOSTIC, PREVENTIVE, THERAPEUTIC AND OTHER USE HAVE
AU7994200A (en) 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6893818B1 (en) * 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
WO2001034802A2 (en) 1999-11-12 2001-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CA2395240A1 (en) 2000-01-13 2001-07-19 Genset S.A. Biallelic markers derived from genomic regions carrying genes involved in central nervous system disorders
WO2001051628A2 (en) 2000-01-14 2001-07-19 Millennium Pharmaceuticals, Inc. Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU3447401A (en) 2000-01-14 2001-07-24 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001059063A2 (en) 2000-01-31 2001-08-16 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20020090672A1 (en) * 2000-01-31 2002-07-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
WO2001055447A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20020132767A1 (en) * 2000-01-31 2002-09-19 Rosen Craig A. Nucleic acids, proteins, and antibodies
WO2001055326A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001243142A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
US20020081590A1 (en) 2000-02-04 2002-06-27 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
US20030170246A1 (en) 2000-02-11 2003-09-11 Corixa Corporation Lipophilin complexes for use in cancer diagnosis and therapy
WO2001060860A2 (en) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use
EP1276751A4 (en) 2000-02-28 2005-04-06 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES
JP2001245671A (ja) 2000-03-07 2001-09-11 Chiba Prefecture ヒト神経芽細胞腫においてクローニングされた新規遺伝子及び新規遺伝子の断片
JP2004502406A (ja) 2000-03-09 2004-01-29 カイロン　コーポレイション ヒト遺伝子およびヒト遺伝子発現産物
AU4592601A (en) 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
WO2001073032A2 (en) 2000-03-27 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CZ20023567A3 (cs) 2000-03-29 2003-11-12 Corixa Corporation Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP1272668B1 (en) 2000-04-03 2007-02-14 Corixa Corporation Methods, compositions and kits for the detection and monitoring of breast cancer
US20020192763A1 (en) * 2000-04-17 2002-12-19 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
US6682888B1 (en) * 2000-05-05 2004-01-27 Incyte Corporation Genes expressed in alzheimer's disease
AU2001261476A1 (en) 2000-05-11 2001-11-20 Lifespan Biosciences, Inc. Nucleic acid sequences for novel gpcrs
CA2411404A1 (en) 2000-05-26 2001-12-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20020082206A1 (en) * 2000-05-30 2002-06-27 Leach Martin D. Novel polynucleotides from atherogenic cells and polypeptides encoded thereby
WO2001094629A2 (en) 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
GB0014185D0 (en) * 2000-06-09 2000-08-02 Novartis Res Found Compound and method
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
AU2001268471A1 (en) 2000-06-16 2002-01-02 Incyte Genomics, Inc. G-protein coupled receptors
US20040072996A1 (en) * 2001-06-15 2004-04-15 Lal Preeti G G-protein coupled receptors
JP2004508019A (ja) 2000-07-28 2004-03-18 コンピュジェン　インコーポレイテッド トランスクリプトームの中に場所を占めるｒｎａ転写物及びスプライス変異体を検出するためのオリゴヌクレオチドライブラリー
EP1942197A1 (de) 2000-09-01 2008-07-09 Epigenomics AG Verfahren zur Bestimmung des Methylierungsgrades von bestimmten Cytosinen in genomischer DNA im Sequenzkontext 5'-CpG-3'
CN1345964A (zh) 2000-09-29 2002-04-24 上海博德基因开发有限公司 一种新的多肽——己糖激酶10.01和编码这种多肽的多核苷酸
AU2001294943A1 (en) 2000-10-02 2002-04-15 Bayer Corporation Nucleic acid sequences differentially expressed in cancer tissue
US20030134283A1 (en) * 2000-10-03 2003-07-17 Peterson David P. Genes regulated in dendritic cell differentiation
EP1325032A2 (en) * 2000-10-05 2003-07-09 Immunex Corporation Nectin polypeptides, polynucleotides, methods of making and use thereof
US20070014801A1 (en) * 2001-01-24 2007-01-18 Gish Kurt C Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
WO2002030268A2 (en) * 2000-10-13 2002-04-18 Eos Biotechnology, Inc. Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
EP1379651A2 (en) 2000-12-07 2004-01-14 Chiron Corporation Human genes and gene expression products isolated from human prostate
AU2002231077A1 (en) 2000-12-19 2002-07-01 Glaxo Group Limited Novel compounds
US20040072264A1 (en) 2000-12-22 2004-04-15 Morris David W. Novel compositions and methods for cancer
US7820447B2 (en) 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
CN1363678A (zh) 2001-01-05 2002-08-14 上海博德基因开发有限公司 一种新的多肽——信号肽酶9.79和编码这种多肽的多核苷酸
US20040029114A1 (en) * 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
WO2002059377A2 (en) * 2001-01-24 2002-08-01 Protein Design Labs Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
WO2002059271A2 (en) 2001-01-25 2002-08-01 Gene Logic, Inc. Gene expression profiles in breast tissue
US20030073144A1 (en) 2001-01-30 2003-04-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
DE20103510U1 (de) 2001-02-28 2001-06-07 LION Bioscience AG, 69120 Heidelberg Genbibliothek
WO2003008583A2 (en) 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
US20040053250A1 (en) * 2001-03-05 2004-03-18 Tang Y. Tom Novel arginine-rich protein-like nucleic acids and polypeptides
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
US7271240B2 (en) * 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US20030087250A1 (en) * 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
AU2002341538A1 (en) 2001-03-27 2003-01-21 Human Genome Sciences, Inc. Human secreted proteins
WO2002097031A2 (en) 2001-03-28 2002-12-05 Incyte Genomics, Inc. Molecules for diagnostics and therapeutics
EP1409504A2 (en) 2001-03-29 2004-04-21 Incyte Genomics, Inc. Secretory molecules
AU2002303219A1 (en) 2001-03-30 2002-10-15 Corixa Corporation Compositions and methods for the therapy and diagnosis of cancer
WO2002079448A2 (en) 2001-03-30 2002-10-10 Incyte Genomics, Inc. G-protein coupled receptors
EP1383929A4 (en) 2001-04-04 2006-06-07 Neurome Inc GENES EXPRESSED IN DARMEPITHELIAL CELLS AND PEYERS 'PATCH M-CELLS
WO2002085298A2 (en) 2001-04-20 2002-10-31 Millennium Pharmaceutical, Inc. Method for detecting breast cancer cells
US20030083263A1 (en) * 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6794501B2 (en) * 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
CA2446788A1 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002092001A2 (en) 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7171311B2 (en) 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
US7189507B2 (en) * 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040076955A1 (en) * 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
WO2003052049A2 (en) 2001-07-09 2003-06-26 Incyte Genomics, Inc. Molecules for disease detection and treatment
AU2002326372A1 (en) 2001-07-12 2003-01-29 Incyte Genomics, Inc. Nucleic acid-associated proteins
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003009814A2 (en) 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
AU2002367815A1 (en) 2001-08-09 2003-10-08 Nuvelo Inc. Novel nucleic acids and secreted polypeptides
US20070015145A1 (en) 2001-08-14 2007-01-18 Clifford Woolf Nucleic acid and amino acid sequences involved in pain
AU2002323179A1 (en) 2001-08-20 2003-03-03 Bristol-Myers Squibb Company G-protein coupled receptor polynucleotides and methods of use thereof
JP2003088388A (ja) * 2001-09-14 2003-03-25 Herikkusu Kenkyusho:Kk 新規な全長ｃＤＮＡ
EP1293569A3 (en) 2001-09-14 2004-03-31 Research Association for Biotechnology Full-length cDNAs
JP2005536439A (ja) * 2001-09-18 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断及び治療のための組成物と方法
CN1412309A (zh) 2001-10-08 2003-04-23 中国人民解放军军事医学科学院放射医学研究所 人支气管上皮细胞恶性转化差异表达基因的cDNA文库及与肺癌病变相关的克隆
MXPA04004072A (es) 2001-10-30 2004-09-06 Johnson & Johnson Metodos para valorar y tratar leucemia.
EP1470247A2 (en) 2001-11-05 2004-10-27 Deutsches Krebsforschungszentrum Novel genetic markers for leukemias
AU2002361610B2 (en) * 2001-11-07 2007-01-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
US20030232350A1 (en) * 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20040115629A1 (en) * 2002-01-09 2004-06-17 Panzer Scott R Molecules for diagnostics and therapeutics
AU2003210518A1 (en) 2002-01-16 2003-09-02 Incyte Genomics, Inc. Molecules for diagnostics and therapeutics
AU2003210266A1 (en) 2002-02-14 2003-09-04 Bioinvent International Ab Treatment, diagnosis and imaging of disease
AU2003223207A1 (en) 2002-03-01 2003-09-16 Exelixis, Inc. SCDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2003076586A2 (en) 2002-03-06 2003-09-18 Incyte Corporation Nucleic acid-associated proteins
JP2003259877A (ja) 2002-03-11 2003-09-16 Sumitomo Pharmaceut Co Ltd 肝線維症疾患マーカーおよびその利用
WO2003083074A2 (en) 2002-03-28 2003-10-09 Idec Pharmaceuticals Corporation Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
US20040101874A1 (en) * 2002-04-12 2004-05-27 Mitokor Inc. Targets for therapeutic intervention identified in the mitochondrial proteome
SI1545613T1 (sl) * 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
JP2004121218A (ja) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
US7408048B2 (en) * 2002-08-09 2008-08-05 Melbourne Health Mammalian grainyhead transcription factors
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
CN1477123A (zh) 2002-08-23 2004-02-25 上海博德基因开发有限公司 一种多肽——转录因子43和编码这种多肽的多核苷酸
AU2003289716A1 (en) * 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
EP1585482A4 (en) 2002-09-25 2009-09-09 Genentech Inc NEW COMPOSITIONS AND METHODS FOR TREATING PSORIASIS
JP2006515318A (ja) 2002-10-29 2006-05-25 ファルマシア・コーポレーション 特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法
US20080213166A1 (en) 2002-11-20 2008-09-04 Biogen Idec Inc. Novel Gene Targets and Ligands that Bind Thereto for Treatment and Diagnosis of Colon Carcinomas
WO2004048599A2 (en) 2002-11-22 2004-06-10 Incyte Corporation Transporters and ion channels
US20040253606A1 (en) 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2004066948A2 (en) 2003-01-29 2004-08-12 Exelixis Inc. Mapcaxs as modifiers of the apc and axin pathways and methods of use
EP1447413A3 (en) 2003-02-14 2006-01-04 Research Association for Biotechnology Full-length human cDNA
WO2004108948A2 (en) 2003-06-04 2004-12-16 President And Fellows Of Harvard College Systems, methods and kits for characterizing phosphoproteomes
KR101438983B1 (ko) * 2003-11-06 2014-09-05 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
WO2008007648A1 (fr) * 2006-07-10 2008-01-17 Institute For Antibodies Co., Ltd. Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
TWI552751B (zh) 2011-06-20 2016-10-11 Ｈ 朗德貝克公司 投予４－（（１ｒ，３ｓ）－６－氯－３－苯基－二氫茚－１－基）－１，２，２－三甲基－哌及其鹽用於治療精神分裂症的方法
US9701019B2 (en) 2011-09-15 2017-07-11 Convergent Information Technologies Gmbh System and method for the automatic generation of robot programs

Also Published As

Publication number Publication date
US20040081653A1 (en) 2004-04-29
US20040083497A1 (en) 2004-04-29
JP4490502B2 (ja) 2010-06-30
US20110201052A1 (en) 2011-08-18
IL166532A (en) 2011-09-27
US20100297006A1 (en) 2010-11-25
EP1576132B1 (en) 2012-08-15
EP1576104A2 (en) 2005-09-21
DK1576170T3 (da) 2012-11-26
EP2332966A1 (en) 2011-06-15
AU2003243151A8 (en) 2004-03-03
EP1576170B1 (en) 2012-08-15
SI1576132T1 (sl) 2012-12-31
US20100297669A1 (en) 2010-11-25
IL166531A (en) 2014-07-31
US7696336B2 (en) 2010-04-13
EP1576170A2 (en) 2005-09-21
US20130267024A1 (en) 2013-10-10
IL166531A0 (en) 2006-01-15
WO2004016733A2 (en) 2004-02-26
EP1576130A2 (en) 2005-09-21
AU2003236553A1 (en) 2004-03-03
SI1576170T1 (sl) 2012-12-31
IL166564A (en) 2012-01-31
US20080181885A1 (en) 2008-07-31
ES2391892T3 (es) 2012-11-30
EP2301954A2 (en) 2011-03-30
JP2009159963A (ja) 2009-07-23
JP2009278988A (ja) 2009-12-03
US20040192597A1 (en) 2004-09-30
CA2493925A1 (en) 2004-02-26
AU2003232116B2 (en) 2008-05-29
WO2004016734A3 (en) 2006-08-24
CA2493923C (en) 2020-02-18
IL233223A (en) 2015-03-31
CA2493923A1 (en) 2004-02-26
WO2004016799A2 (en) 2004-02-26
EP2301954A3 (en) 2012-05-09
AU2003232116A1 (en) 2004-03-03
AU2008207531A1 (en) 2008-09-18
AU2003258269A1 (en) 2004-03-03
IL166655A (en) 2010-06-16
WO2004016799A3 (en) 2007-04-05
WO2004016762A3 (en) 2007-01-18
PT1576132E (pt) 2012-10-31
CA2493928A1 (en) 2004-02-26
US20070231261A1 (en) 2007-10-04
PT1576170E (pt) 2012-11-05
EP1576170A4 (en) 2008-07-23
WO2004016736A2 (en) 2004-02-26
US20130177569A1 (en) 2013-07-11
AU2003228717B2 (en) 2008-02-21
US20110195019A1 (en) 2011-08-11
US8426571B2 (en) 2013-04-23
US20070298424A1 (en) 2007-12-27
US20040053348A1 (en) 2004-03-18
US7612172B2 (en) 2009-11-03
CA2493928C (en) 2014-04-01
JP2006513724A (ja) 2006-04-27
IL166564A0 (en) 2006-01-15
US20040213778A1 (en) 2004-10-28
DK1576132T3 (da) 2012-10-01
EP1576132A4 (en) 2007-09-05
EP1576132A2 (en) 2005-09-21
WO2004016762A2 (en) 2004-02-26
WO2004016733A3 (en) 2006-03-16
CA2493921A1 (en) 2004-02-26
AU2003243151A1 (en) 2004-03-03
AU2003258269B2 (en) 2007-06-28
IL233223A0 (en) 2014-07-31
IL166532A0 (en) 2006-01-15
US7115727B2 (en) 2006-10-03
AU2003258269C1 (en) 2004-03-03
EP1576130A4 (en) 2007-08-08
AU2003236553C1 (en) 2008-05-01
IL166655A0 (en) 2006-01-15
AU2003236553B2 (en) 2007-09-20
US8057996B2 (en) 2011-11-15
WO2004016736A3 (en) 2006-10-05
JP2009278977A (ja) 2009-12-03
JP2010142228A (ja) 2010-07-01
WO2004016734A2 (en) 2004-02-26
IL200404A0 (en) 2010-04-29
ES2392341T3 (es) 2012-12-07
US20070059729A1 (en) 2007-03-15
EP1576104A4 (en) 2007-10-10
IL200404A (en) 2014-07-31
US8604169B2 (en) 2013-12-10
JP2006511232A (ja) 2006-04-06
AU2003228717A1 (en) 2004-03-03
CY1113247T1 (el) 2016-04-13
CA2493921C (en) 2015-12-08
US20090252747A1 (en) 2009-10-08
US7250498B2 (en) 2007-07-31

Similar Documents

Publication Publication Date Title
CA2493923C (en) Nucleic acids and corresponding proteins entitled 191p4d12(b) useful in treatment and detection of cancer
CA2462653C (en) Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
CA2459318C (en) Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
AU2008258185B2 (en) Prostate stem cell antigen (PSCA) variants and subsequences thereof
AU2010226920B2 (en) Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
US7968090B2 (en) Nucleic acids and corresponding proteins entitled 191P4D12(b) useful in treatment and detection of cancer
AU2002362105B2 (en) Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer
CA2481503A1 (en) Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
CA2522994C (en) Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer
CA2514058C (en) Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
AU2009208065B2 (en) Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
AU2008202217B2 (en) Nucleic acids and corresponding proteins entitled 191PAD12(b) useful in treatment and detection of cancer
AU2007237184B8 (en) Nucleic acids and corresponding proteins entitled 202P5A5 useful in treatment and detection of cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200323

EEER Examination request

Effective date: 20200323

EEER Examination request

Effective date: 20200323

MKEX Expiry

Effective date: 20230424